Veeva Systems (VEEV) Stock Analysis & Winston Score
Veeva Systems makes software specifically for life sciences companies — think pharmaceutical firms, biotech startups, and medical device makers. Its main products help these companies manage their sales teams, run clinical trials, store regulatory documents, and track data about doctors and hospitals. Veeva is one of the largest cloud software providers focused exclusively on the life sciences industry. Veeva makes money by charging customers annual subscription fees to use its software, which gives it predictable, recurring revenue. It operates globally, serving over 1,000 customers across North America, Europe, and Asia, and generates roughly $2.7 billion in annual revenue. Its moat comes from deep integration into customers' core workflows, making it costly and disruptive to switch to a competitor. The key risk is that Veeva is migrating its core platform from Salesforce's infrastructure to its own, called Vault CRM, and how smoothly that transition goes will be a major factor in whether it retains and grows its customer base.
Winston Score: 71/100 — Strong
A high-quality business with solid fundamentals.
- Quality: Good (19/30)
- Growth: Exceptional (18/20)
- Cash Flow: Good (6/10)
- Stability: Exceptional (10/10)
- Valuation: Good (6/10)
- Ownership: Good (8/15)


